MEBROFENIN - mebrofenin injection, powder, lyophilized, for solution 
AnazaoHealth Corporation

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.



Dear Medical Professional,

Per your order, we have compounded Mebrofenin as a sterile solution. The characteristics of this preparation are


AnazaoHealth supplies compounded Mebrofenin for the preparation of Tc-99m Mebrofenin. Each reaction vial contains 10 mg Mebrofenin and 0.2 mg tin as stannous chloride. The vial is back filled with nitrogen gas after lyophilization. The vial may contain a partial vacuum.


Technetium Tc-99m Mebrofenin by intravenous administration is indicated as a hepatic imaging agent, used in the diagnosis of liver disease


The suggested intravenous dose range of Technetium Tc 99m Mebrofenin in the average patient (70 kg) is:

Nonjaundiced patient: 74 - 185 MBq (2-5 mCi)

Patient with serum bilirubin level greater than 1.5 mg/dL: 111-370 MBq (3-10 mCi)

The patient should be in a fasting state, 4 hours is preferable. False positives (non-visualization) may result if the gallbladder has been emptied by ingestion of food.

An interval of at least 24 hours should be allowed before repeat examination


To prepare injection, follow this aseptic procedure:

  1. Waterproof gloves should be worn during the preparation procedure.
  2. Snap off the plastic lid and place room temperature reaction vial in an appropriate lead shield.
  3. Swab the rubber closure of the vial with a germicide.
  4. Inject 1 – 3 ml Sterile additive free sodium pertechnetate Tc-99m injection containing up to 740 MBq (20 mCi) into the vial. Be sure to maintain inert atmosphere in vial by introducing as little air as possible during reconstitution. NOTE: If sodium pertechnetate Tc-99m injection must be diluted, use only preservative free Sodium Chloride Injection USP.
  5. Secure the lead shield cover. Swirl the vial gently to mix contents and let stand 3 to 5 minutes prior to use.
  6. Record the date and time of preparation on a pressure-sensitive label.
  7. Affix pressure-sensitive label to shield.
  8. Examine vial contents; if the solution is not clear and free of particulate matter and discoloration on visual inspection, it should not be used.
  9. Measure the radioactivity by suitable calibration system and record prior to patient administration.
  10. Appropriate quality control is recommended.
  11. Use within 12 hours of preparation


Figure 1

C:\Users\achai\Desktop\NDC Project-AC 2012\Mebrofenin\Mebrolabel.JPG
mebrofenin injection, powder, lyophilized, for solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:51808-216
Route of AdministrationINTRAVENOUS
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Inactive Ingredients
Ingredient NameStrength
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:51808-216-011 in 1 KIT
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other06/19/2012
Labeler - AnazaoHealth Corporation (011038762)
NameAddressID/FEIBusiness Operations
AnazaoHealth Corporation011038762MANUFACTURE(51808-216)

Revised: 6/2012
Document Id: 4d7406b4-8bcd-40f0-a31f-975f5b811da7
Set id: aeefa6ee-f45c-49fe-b38e-6cfd99a33030
Version: 3
Effective Time: 20120619
AnazaoHealth Corporation